Safety of ventricular tachycardia ablation in clinical practice: findings from 9699 hospital discharge records.

ABSTRACT:

Background

Outcomes of ventricular tachycardia (VT) ablation have been described in clinical trials and single-center studies. We assessed the safety of VT ablation in clinical practice.

Methods and results

Using administrative hospitalization data between 1994 and 2011, we identified hospitalizations with primary diagnosis of VT (International Classification of Diseases-9 Clinical Modification code: 427.1) and cardiac ablation (International Classification of Diseases-9 Clinical Modification code: 37.34). We quantified in-hospital adverse events (AEs), including death, stroke, intracerebral hemorrhage, pericardial complications, hematoma or hemorrhage, blood transfusion, or cardiogenic shock. Secondary outcomes included major AEs (stroke, tamponade, or death) and death. Mul

SUBMITTER: Katz DF 

PROVIDER: S-EPMC9893573 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature